Table 3.
Stepwise Regression Model Examining Which Potentially Modifiable Factors Uniquely Predict Self-Report Adherence at Baseline
| Predictor | Unstnd. b | SE | p | Zero-Order r | Part r | Part r2 |
|---|---|---|---|---|---|---|
| Constant | 7.18 | 0.95 | <0.001 | - | - | - |
| AET type | −0.02 | 0.21 | 0.94 | 0.07 | −0.01 | 0.00 |
| Menopausal status | −0.14 | 0.10 | 0.18 | 0.02 | −0.11 | 0.01 |
| Time on AET | 0.00 | 0.00 | 0.99 | −0.06 | 0.01 | 0.00 |
| Side effect severity | −0.11 | 0.03 | <0.001* | −0.49 | −0.30 | 0.09 |
| Self-efficacy | 0.06 | 0.02 | <0.01* | 0.37 | 0.23 | 0.05 |
| Medication/healthcare system-related barriers | −0.10 | 0.04 | 0.02* | −0.46 | −0.19 | 0.04 |
Notes: AET type, menopausal status, and time taking AET were included as covariates. *p<0.05. Model summary: R2=0.36, F[6, 102]=9.59, p<0.001.
Abbreviation: AET, adjuvant endocrine therapy.